NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- Written by PR Newswire

Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...

Leaders across Australia are asking themselves how they can ensure their employees get the most out of AI. We recently conducted research to help an...

A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...

Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience ...

We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...

Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...